To allow sustained local delivery of GM-CSF as an adjuvant in an anti-cancer vaccine, we developed an encapsulated cell technology in which genetically modified cells are loaded into a biocompatible, semipermeable capsule which can secrete human or murine GM-CSF. The gene discussed is CSF2; the disease is cancer.